SBFMW Sunshine Biopharma Inc. warrant
$0.03▲ +0.00%
Healthcare
Other
Volume 0
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
0.03 - 0.03
% vs 50 MA
-59.61%
% vs 200 MA
–%
RSI-14
43.1
MACD Histogram
+0.0000
Beta (1Y vs SPY)
-1.31
Free Cash Flow
-$923,097
Gross Rev
$9.26M
Gross Profit
$2.43M
EBITDA
-$1.53M
COGS
$6.84M
Operating Exp
$4.04M
Operating Income
-$1.61M
EBIT
-$1.61M
Pretax Income
-$1.56M
Net Income
-$1.56M
Price & Volume History
Loading chart…
Recent News
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
ACCESS Newswire · Oct 22, 2026 9:00 AM ET
Sunshine Biopharma Closes $6 Million Equity Offering
MT Newswires · Oct 12, 2026 6:22 AM ET
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
ACCESS Newswire · Oct 9, 2026 11:17 AM ET
Sunshine Biopharma Prices $6 Million Public Offering at $0.55 Per Unit, Raising Dilution Concerns
InvestorsHub · Oct 8, 2026 10:40 AM ET
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
ACCESS Newswire · Sep 24, 2026 9:00 AM ET
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
ACCESS Newswire · Sep 16, 2026 9:00 AM ET
EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
Benzinga · Sep 16, 2026 8:31 AM ET
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
ACCESS Newswire · Aug 31, 2026 9:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SBFMW's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.